M. Cecilia Monge B.

A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer.

M. Cecilia Monge B., Changqing Xie, Seth M. Steinberg et al. · Journal of Clinical Oncology · 2020 · 19 citations

Life Sciences, Immunology, Pharmacology +17

A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).

Changqing Xie, M. Cecilia Monge B., Donna Mabry‐Hrones et al. · Journal of Clinical Oncology · 2023 · 17 citations

Life Sciences, Immunology, Oncology +11

Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.

Arjun Mittra, Geraldine O’Sullivan Coyne, Khanh Tu et al. · Journal of Clinical Oncology · 2019 · 11 citations

Medicine, Oncology, Pharmacology +14